In a new job - May 2, 2019
LEO Pharma appoints new General Manager Nordics
Klaus Abel has been appointed to lead LEO Pharma across the Nordic region. Klaus Abel moves into the new role from Lundbeck where he was for 19 years. While at Lundbeck, he held senior roles in Global Marketing and in Commercial Operations in addition to Managing Director positions in Australia/New Zealand from 2007-2011 and Italy from […]
Agreement - April 10, 2019
LEO Pharma and Elektrofi expand their partnership
The two companies have announced an expansion of their partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology. As part of the agreement LEO Pharma and Elektrofi will initially co-develop two specific antibodies. The agreement includes an option to a […]
Clinical Trials - April 5, 2019
LEO Pharma initiates clinical trial of microarray patches for psoriasis treatment
Together with LTS Lohmann Therapie-Systeme the company will start the first-ever clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients. Microarray patch A microarray patch […]
New Market - August 7, 2017
LEO Pharma receives marketing authorization for Kyntheum
LEO Pharma has announced that the European Commission has granted marketing authorization for Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum is the first and only biologic that selectively targets the IL-17 receptor subunit A. It is different from existing therapies. […]
Clinical Trials - August 3, 2017
LEO Pharma ranks second in Global Clinical Trials Transparency Audit
New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information. The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry. LEO Pharma is ranked at number two out of the 50 pharmaceutical companies evaluated. AllTrials is an international campaign that calls for […]
Biotech Business - June 21, 2017
LEO Pharma invests in Novopyxis
LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin. The hand-held aerosol device will be clinically tested on people with alopecia. Alopecia is an autoimmune disease leading to hair loss from all or […]
